Treatment for COVID-19

Phase-Based Progress Estimates
Urgent Care Clinical Trials Easley, Easley, SC
COVID-19+3 More
Any Age
All Sexes
What conditions do you have?

Study Summary

This study is designed as a prospective, multicentric, sample collection study. The collected samples will be used for diagnostic research, product development and validation of the Panbio™ COVID-19/ Flu A&B Rapid Panel for the qualitative detection of COVID-19 antigen, Influenza A antigen (H1N1 and H3N2), and Influenza B antigen in human nasal and nasopharyngeal swabs by the study sponsor, Abbott.

Eligible Conditions

  • COVID-19
  • Influenza A Virus Infection
  • Influenza Type B

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 6 months

6 months
Nasal and Nasopharyngeal Sample Collection

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

665 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: Urgent Care Clinical Trials Easley · Easley, SC
N/AFirst Recorded Clinical Trial
1 TrialsResearching COVID-19
0 CompletedClinical Trials

Eligibility Criteria

Age Any Age · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.